Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

Photo illustration of Wegovy and a weight scale. Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical ...

In recent trading, shares of Hims & Hers Health Inc (Symbol: HIMS) have crossed above the average analyst 12-month target price of $20.50, changing hands for $22.77/share. When a stock reaches the ...

The companies will sell the drug at a reduced price of $499 a month. Consumers looking to start the popular weight loss drug Wegovy but lacking insurance coverage will soon have a new option. Novo ...

Hims & Hers, the high-flying telehealth company that rapidly ascended from a buzzy startup selling Viagra to a multibillion-dollar business with a Super Bowl ad, had a hard week. The San Francisco ...

Hims & Hers Health, Inc. (NYSE:HIMS) shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here’s a look at what’s going on. What To Know: In late June, shares ...

Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective raised by Bank of America from $21.00 to $22.00 in a report released on Tuesday morning,Benzinga reports. They currently have an ...

The move will rapidly expand Hims & Hers’ reach, which has a current base of 2.4 million U.S. customers. As the only digital health company with over a decade of operations across Germany, France, ...